{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:25:49Z","timestamp":1793647549352,"version":"4.5.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"\n Importance<\/jats:title>\n Circulating tumor tissue\u2013modified viral (TTMV) human papillomavirus (HPV) DNA is a dynamic, clinically relevant biomarker for HPV-positive oropharyngeal squamous cell carcinoma. Reasons for its wide pretreatment interpatient variability are not well understood.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize clinicopathologic factors associated with TTMV HPV DNA.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study included patients evaluated for HPV-positive oropharyngeal squamous cell carcinoma at Dana-Farber Cancer Institute in Boston, Massachusetts, between December 2019 and January 2022 and who were undergoing curative-intent treatment.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Clinicopathologic characteristics including demographic variables, tumor and nodal staging, HPV genotype, and imaging findings.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Pretreatment circulating TTMV HPV DNA from 5 genotypes (16, 18, 31, 33, and 35) assessed using a commercially available digital droplet polymerase chain reaction\u2013based assay, considered as either detectable\/undetectable or a continuous score (fragments\/mL).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 110 included patients, 96 were men (87%) and 104 were White (95%), with a mean (SD) age of 62.2 (9.4) years. Circulating TTMV HPV DNA was detected in 98 patients (89%), with a median (IQR) score of 315 (47-2686) fragments\/mL (range, 0-60\u202f061 fragments\/mL). Most detectable TTMV HPV DNA was genotype 16 (n\u2009=\u200986 [88%]), while 12 patients (12%) harbored other genotypes. Circulating TTMV HPV DNA detection was most strongly associated with clinical N stage. Although few patients had clinical stage N0 disease, only 4 of these 11 patients (36%) had detectable DNA compared with 94 of 99 patients (95%) with clinical stage N1 to N3 disease (proportion difference, 59%; 95% CI, 30%-87%). Among patients with undetectable TTMV HPV DNA, more than half (7 of 12 [58%]) had clinical stage N0 disease. The TTMV HPV DNA prevalence and score increased with progressively higher clinical nodal stage, diameter of largest lymph node, and higher nodal maximum standardized uptake value on positron emission tomography\/computed tomography. In multivariable analysis, clinical nodal stage and nodal maximum standardized uptake value were each strongly associated with TTMV HPV DNA score. Among 27 surgically treated patients, more patients with than without lymphovascular invasion had detectable TTMV HPV DNA (12 of 12 [100%] vs 9 of 15 [60%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study, circulating TTMV HPV DNA was statistically significantly associated with nodal disease at HPV-positive OPSCC diagnosis. The few patients with undetectable levels had predominantly clinical stage N0 disease, suggesting assay sensitivity for diagnostic purposes may be lower among patients without cervical lymphadenopathy. Mechanisms underlying this association, and the use of this biomarker for surveillance of patients with undetectable baseline values, warrant further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2022.3282","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T11:11:57Z","timestamp":1666869117000},"page":"1120","source":"Crossref","is-referenced-by-count":80,"title":["Association of Pretreatment Circulating Tumor Tissue\u2013Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer"],"prefix":"10.1001","volume":"148","author":[{"given":"Eleni M.","family":"Rettig","sequence":"first","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette A.","family":"Wang","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc-Anh","family":"Tran","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Neuroradiology, Department of Radiology, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Carey","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanujit","family":"Dey","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Guenette","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Neuroradiology, Department of Radiology, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Margalit","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosh","family":"Sethi","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Uppaluri","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Tishler","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Annino","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Goguen","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie Y.","family":"Jo","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"36","key":"ooi220065r1","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","article-title":"Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.","volume":"31","author":"Chaturvedi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"ooi220065r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2907","article-title":"Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020-2045.","volume":"7","author":"Zhang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"ooi220065r3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15","key":"ooi220065r4","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer.","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ooi220065r5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamaoto.2022.0159","article-title":"Association of plasma circulating tumor HPV DNA with HPV-related oropharynx cancer.","volume":"148","author":"Tewari","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"10","key":"ooi220065r6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"ooi220065r7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdy251","article-title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.","volume":"29","author":"Hanna","year":"2018","journal-title":"Ann Oncol"},{"key":"ooi220065r8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0562","article-title":"Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.","author":"Berger","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ooi220065r9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ijc.v151.7","article-title":"Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.","volume":"151","author":"Rettig","year":"2022","journal-title":"Int J Cancer"},{"key":"ooi220065r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105805","article-title":"Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.","volume":"128","author":"Mattox","year":"2022","journal-title":"Oral Oncol"},{"issue":"2","key":"ooi220065r11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma.","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ooi220065r12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2022.02.012","article-title":"Detectable postoperative circulating tumor human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma.","volume":"113","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"ooi220065r13","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.v128.11","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.","volume":"128","author":"O\u2019Boyle","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"ooi220065r14","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1007\/s00330-020-07281-y","article-title":"The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: a systematic review and diagnostic meta-analysis.","volume":"31","author":"Park","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"ooi220065r15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1971400917694048","article-title":"Computed tomography detection of extracapsular spread of squamous cell carcinoma of the head and neck in metastatic cervical lymph nodes.","volume":"30","author":"Carlton","year":"2017","journal-title":"Neuroradiol J"},{"issue":"5","key":"ooi220065r16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cncr.31841","article-title":"The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status.","volume":"125","author":"Faraji","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"ooi220065r17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jmiro.v63.4","article-title":"Predictive value of computed tomography in identifying extracapsular spread of cervical lymph node metastases in p16 positive oropharyngeal squamous cell carcinoma.","volume":"63","author":"Noor","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"26","key":"ooi220065r20","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2006.05.9493","article-title":"Prediction of breast tumor progression by integrity of free circulating DNA in serum.","volume":"24","author":"Umetani","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"ooi220065r21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3390\/ijms17122131","article-title":"Circulating cell-free DNA levels could predict oncological outcomes of patients undergoing esophagectomy for esophageal squamous cell carcinoma.","volume":"17","author":"Hsieh","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"ooi220065r22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12253-017-0380-6","article-title":"Diagnostic value of circulating free DNA integrity and global methylation status in gall bladder carcinoma.","volume":"25","author":"Kumari","year":"2019","journal-title":"Pathol Oncol Res"},{"issue":"10","key":"ooi220065r23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/cancers13102313","article-title":"Circulating cell-free DNA as a prognostic biomarker in resectable ampullary cancer.","volume":"13","author":"Shyr","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"29","key":"ooi220065r24","doi-asserted-by":"publisher","first-page":"20467","DOI":"10.18632\/oncotarget.v9i29","article-title":"Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma.","volume":"9","author":"Yamamoto","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"ooi220065r25","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/j.ijrobp.2011.05.061","article-title":"Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients.","volume":"82","author":"Cao","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"ooi220065r26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamaoncol.2015.2524","article-title":"Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus-related oropharyngeal carcinoma.","volume":"1","author":"Rettig","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"ooi220065r27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1940-6207.CAPR-19-0185","article-title":"Evaluating the utility and prevalence of HPV biomarkers in oral rinses and serology for HPV-related oropharyngeal cancer.","volume":"12","author":"D\u2019Souza","year":"2019","journal-title":"Cancer Prev Res (Phila)"},{"issue":"7","key":"ooi220065r28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaoncol.2019.0439","article-title":"Association of oral human papillomavirus DNA persistence with cancer progression after primary treatment for oral cavity and oropharyngeal squamous cell carcinoma.","volume":"5","author":"Fakhry","year":"2019","journal-title":"JAMA Oncol"},{"key":"ooi220065r29","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1200\/JCO.2021.39.15_suppl.6063","article-title":"Evaluating a clinically validated circulating tumor HPV DNA assay in saliva as a proximal biomarker in HPV+ oropharyngeal squamous cell carcinoma.","volume":"39","author":"Gerndt","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"ooi220065r30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","article-title":"Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.","volume":"67","author":"Lydiatt","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ooi220065r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104488","article-title":"HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.","volume":"100","author":"Chatfield-Reed","year":"2020","journal-title":"Oral Oncol"},{"issue":"6","key":"ooi220065r32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamaoncol.2015.6587","article-title":"Human papillomavirus genotype association with survival in head and neck squamous cell carcinoma.","volume":"2","author":"Bratman","year":"2016","journal-title":"JAMA Oncol"},{"key":"ooi220065r33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.oraloncology.2016.08.019","article-title":"Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma.","volume":"61","author":"Mazul","year":"2016","journal-title":"Oral Oncol"},{"key":"ooi220065r18","volume-title":"Categorical Data Analysis","author":"Agresti","year":"2003"},{"key":"ooi220065r19","doi-asserted-by":"crossref","DOI":"10.1142\/q0019","volume-title":"Statistics and Experimental Design for Psychologists: A Model Comparison Approach","author":"Allen","year":"2017"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2797693\/jamaotolaryngology_rettig_2022_oi_220065_1669826714.31202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T11:02:01Z","timestamp":1670497321000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2797693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2022.3282","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}